G protein-coupled receptor 4Genealiases: GPR6C.l · hGPR4
Q-omics provides the consensus-scored GPR4 profile across patient tissues and cancer cell-line models. GPR4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GPR4 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, GPR4 RNA expression shows 16,590 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, HNSC, and THYM as cancer lineages where GPR4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR4 survival associations across molecular data types. GPR4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR4 RNA expression–survival associations across cancer types. High GPR4 expression shows unfavorable associations in KIRP, MESO, ACC, LGG and BLCA, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for GPR4 RNA expression.
This table summarizes GPR4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GPR4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR4 shows lower tumor expression in LUAD and higher tumor expression in HNSC, KIRC, COAD, LIHC and STAD. The HNSC box plot shows higher GPR4 RNA expression in tumor versus normal tissue (log2 FC = +2.231, t-test p < 0.001).
This table shows molecular features associated with GPR4 in patient tissues and cancer cell lines. In patient samples, GPR4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
